CYT
Closed
Cyteir Therapeutics Inc
3.01
-0.01 (-0.33%)
Last Update: 12 Apr 2024 16:30:00
Yesterday: 3.02
Day's Range: 3.01 - 3.01
Send
sign up or login to leave a comment!
When Written:
1.82
Cyteir Therapeutics Inc is a biotechnology company that focuses on developing novel cancer therapies. The company was founded in 2013 by Dr. Kevin Mills and Dr. Timothy Shannon, both of whom have extensive experience in the biotech industry.
Cyteir's lead drug candidate, CYT-0851, is a small molecule inhibitor of RAD51, a protein that plays a key role in DNA repair. By inhibiting RAD51, CYT-0851 is designed to sensitize cancer cells to DNA damage and prevent them from repairing themselves, ultimately leading to cell death.
Cyteir has also developed a proprietary platform technology called the Synthetic Lethality Engine, which enables the identification of novel drug targets and drug combinations that selectively kill cancer cells while sparing normal cells.
The company is headquartered in Lexington, Massachusetts and has raised over $100 million in funding to date from investors such as Venrock, New Enterprise Associates, and Lightstone Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Cyteir's lead drug candidate, CYT-0851, is a small molecule inhibitor of RAD51, a protein that plays a key role in DNA repair. By inhibiting RAD51, CYT-0851 is designed to sensitize cancer cells to DNA damage and prevent them from repairing themselves, ultimately leading to cell death.
Cyteir has also developed a proprietary platform technology called the Synthetic Lethality Engine, which enables the identification of novel drug targets and drug combinations that selectively kill cancer cells while sparing normal cells.
The company is headquartered in Lexington, Massachusetts and has raised over $100 million in funding to date from investors such as Venrock, New Enterprise Associates, and Lightstone Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!